Printer Friendly

Studies in Galveston.

SCH 417690 (vicraviroc) is a new HIV medication that is under investigation and not yet approved by the Food and Drug Administration (FDA). It is a member of a new class of potential HIV reeds called "CCR5 receptor antagonists" that block one way HIV enters and infects T cells. This study will examine whether this new drug can decrease the amount of HIV in the blood when used with Norvir (as a booster) and other HIV meds. Individuals interested in participating in this study must have a T cell count of 50 or greater and an HIV viral load of 5,000 or greater. In addition, interested individuals must be on HIV meds that include Norvir. For more information about this study (known as ACT6 A5211), contact Mike Reardon at 409-747-0214 or 1-877-324-2288.

ACTG A5197 is a study looking at a "therapeutic vaccine" to see what kind of role it may have in the long-term control of HIV. Therapeutic vaccines are for individuals that already have HIV. These vaccines are intended to slow the progression of HIV in the body. Individuals who participate in this study will be randomly assigned (by chance, like flipping a coin) to receive 3 injections of the vaccine or a placebo. Then, participants will stop taking their HIV meds for 16 weeks. During this interruption, researchers will look at how long the vaccine continues to work. Study participants then have the option to restart meds or continue to stay off them through week 87 of the study. The final phase of the study is a long-term follow-up lasting about 3 years. People interested in this study must be 18 to 50 years old and HIV+. Interested individuals must have a T count of 500 or greater. They also must have a viral load less than 50 (and less than 500 for at least 2 years). Contact Gerianne Casey at 409-747-0214 or 1-877-324-2288 for complete details on this study.

ACT6 A5146 is a study that will examine the effect of adjusting the dose of a patient's HIV protease inhibitor (PI) on controlling HIV viral load levels. A PI is an HIV reed that interferes with HIV's ability to reproduce. Specifically, this study will examine whether higher doses of PI drugs control HIV better than standard doses of PI drugs that HIV+ people already receive. The researchers want to know if the increased amount of PIs is better at lowering the amount of HIV in the blood. Each person's levels of PI drugs will be adjusted using a measurement called "therapeutic drug monitoring" (TDM). Individuals interested in participating in this study must have a viral load greater than 1,000 and must be taking HIV medications that include a PI. Contact Gerianne Casey at 409-747-0214 or 1-800-324-2288 for complete information on this study.
COPYRIGHT 2005 The Center for AIDS: Hope & Remembrance Project
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:New medications in progress for HIV; vicraviroc; therapeutic vaccine; protease inhibitor
Publication:HIV Treatment: ALERTS!
Geographic Code:1USA
Date:Apr 1, 2005
Words:466
Previous Article:SMART Study.
Next Article:The 14th Conference on Retroviruses and Opportunistic Infections (CROI): Los Angeles, February 25th-28th.
Topics:


Related Articles
Treating HIV in 2003.
Conference highlights.
Atazanavir expanded access. (Treatment News).
Basic science priorities for therapeutics research.
The hepatitis C drug development pipeline.
Welcome.
Tipranavir.
Research on postexposure prophylaxis for HIV.
HIV/AIDS research after HAART.
The next line of attack: the previous generation of anti-HIV drugs changed AIDS from an untreatable epidemic into a survivable disease. The next crop...

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters